Daiichi Buys 52.5% Stake in Ranbaxy

Daiichi Sankyo (Tokyo) says it has completed the acquisition of a majority stake, or 52.5%, of Ranbaxy Laboratories (Gurgaon, India). Ranbaxy will continue to operate as an autonomous company and will closely work with Daiichi to explore growth opportunities, Daiichi says. Daiichi signed a deal with Ranbaxy last June to acquire shares from Ranbaxy’s founders, the Singh family, and to buy shares through an open offer from ordinary shareholders (CW, June 9/16, p. 33). “The substantial cash being infused by Daiichi Sankyo at this stage will be used to...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers